Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD20/CD30 chimeric antigen receptor T cell therapy - Shanghai First Song Biotechnology

Next Previous
X
Search
Drug Profile

Anti CD20/CD30 chimeric antigen receptor T cell therapy - Shanghai First Song Biotechnology

Alternative Names: Anti CD30/CD20 chimeric antigen receptor T cell therapy - Shanghai First Song Biotechnology; Anti-CD20/CD30-CAR-T cell therapy - Shanghai First Song Biotechnology

Latest Information Update: 16 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai First Song Biotechnology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Lymphoma

Most Recent Events

  • 24 Aug 2024 Phase-0 for Lymphoma (In adolescents, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06532643)
  • 07 Aug 2024 Shanghai First Song Biotechnology plans phase I trial in Lymphoma (Late-stage disease, Second-line therapy and greater, In Adolescents) in China in August 2024 (IV) (NCT06532643)
  • 01 Aug 2024 Preclinical trials in Lymphoma in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top